vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $838.0K, roughly 123.7× Prime Medicine, Inc.). Twist Bioscience Corp runs the higher net margin — -29.4% vs -5498.7%, a 5469.3% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -61.6%). Twist Bioscience Corp produced more free cash flow last quarter ($-34.8M vs $-37.5M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
PRME vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $103.7M |
| Net Profit | $-46.1M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -5800.5% | -31.7% |
| Net Margin | -5498.7% | -29.4% |
| Revenue YoY | -61.6% | 16.9% |
| Net Profit YoY | -9.0% | 3.4% |
| EPS (diluted) | $-0.22 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $103.7M | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $2.2M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $591.0K | — | ||
| Q4 23 | $0 | — |
| Q4 25 | $-46.1M | $-30.5M | ||
| Q3 25 | $-50.6M | — | ||
| Q2 25 | $-52.6M | — | ||
| Q1 25 | $-51.9M | — | ||
| Q4 24 | $-42.3M | — | ||
| Q2 24 | $-55.3M | — | ||
| Q1 24 | $-45.8M | — | ||
| Q4 23 | $-65.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -5800.5% | -31.7% | ||
| Q3 25 | -4406.0% | — | ||
| Q2 25 | -4787.2% | — | ||
| Q1 25 | -3603.3% | — | ||
| Q4 24 | -2025.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -8179.5% | — | ||
| Q4 23 | — | — |
| Q4 25 | -5498.7% | -29.4% | ||
| Q3 25 | -4129.1% | — | ||
| Q2 25 | -4716.7% | — | ||
| Q1 25 | -3568.8% | — | ||
| Q4 24 | -1936.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -7743.0% | — | ||
| Q4 23 | — | — |
| Q4 25 | $-0.22 | $-0.50 | ||
| Q3 25 | $-0.32 | — | ||
| Q2 25 | $-0.41 | — | ||
| Q1 25 | $-0.40 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q2 24 | $-0.46 | — | ||
| Q1 24 | $-0.44 | — | ||
| Q4 23 | $-0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $456.1M |
| Total Assets | $342.7M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $197.9M | ||
| Q3 25 | $71.4M | — | ||
| Q2 25 | $53.8M | — | ||
| Q1 25 | $91.9M | — | ||
| Q4 24 | $182.5M | — | ||
| Q2 24 | $55.6M | — | ||
| Q1 24 | $94.2M | — | ||
| Q4 23 | $41.6M | — |
| Q4 25 | $120.9M | $456.1M | ||
| Q3 25 | $161.8M | — | ||
| Q2 25 | $60.9M | — | ||
| Q1 25 | $106.9M | — | ||
| Q4 24 | $153.1M | — | ||
| Q2 24 | $196.6M | — | ||
| Q1 24 | $243.8M | — | ||
| Q4 23 | $133.1M | — |
| Q4 25 | $342.7M | $638.1M | ||
| Q3 25 | $385.0M | — | ||
| Q2 25 | $279.0M | — | ||
| Q1 25 | $328.2M | — | ||
| Q4 24 | $297.5M | — | ||
| Q2 24 | $259.7M | — | ||
| Q1 24 | $311.4M | — | ||
| Q4 23 | $193.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $-37.5M | $-34.8M |
| FCF MarginFCF / Revenue | -4480.4% | -33.5% |
| Capex IntensityCapex / Revenue | 34.6% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-24.8M | ||
| Q3 25 | $-35.0M | — | ||
| Q2 25 | $-41.4M | — | ||
| Q1 25 | $-48.9M | — | ||
| Q4 24 | $16.2M | — | ||
| Q2 24 | $-45.5M | — | ||
| Q1 24 | $-67.7M | — | ||
| Q4 23 | $-43.9M | — |
| Q4 25 | $-37.5M | $-34.8M | ||
| Q3 25 | $-35.3M | — | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q2 24 | $-47.4M | — | ||
| Q1 24 | $-70.0M | — | ||
| Q4 23 | $-45.7M | — |
| Q4 25 | -4480.4% | -33.5% | ||
| Q3 25 | -2880.5% | — | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -11849.6% | — | ||
| Q4 23 | — | — |
| Q4 25 | 34.6% | 9.6% | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 141.0% | — | ||
| Q1 25 | 166.6% | — | ||
| Q4 24 | 82.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 393.2% | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRME
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
